MedStar Authors catalog › Details for: Treatment of ST-segment elevation myocardial infarction during COVID-19 pandemic. [Review]
Normal view MARC view ISBD view

Treatment of ST-segment elevation myocardial infarction during COVID-19 pandemic. [Review]

by Yerasi, Charan; Case, Brian C; Forrestal, Brian J; Chezar-Azerrad, Chava; Hashim, Hayder; Ben-Dor, Itsik; Satler, Lowell F; Mintz, Gary S; Waksman, Ron.
Citation: Cardiovascular Revascularization Medicine. 2020 May 21.Journal: Cardiovascular revascularization medicine : including molecular interventions.Published: ; 2020ISSN: 1878-0938.Full author list: Yerasi C; Case BC; Forrestal BJ; Chezar-Azerrad C; Hashim H; Ben-Dor I; Satler LF; Mintz GS; Waksman R.UI/PMID: 32471712.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal Article | ReviewOnline resources: Click here to access online Digital Object Identifier: (Click here) Abbreviated citation: Cardiovasc Revasc Med. 2020 May 21.Abstract: The number of cases of the coronavirus-induced disease-2019 (COVID-19) continues to increase exponentially worldwide. In this crisis situation, the management of ST-segment elevation myocardial infarction (STEMI) is challenging. In this review, we outline the risk and benefits of primary PCI vs. thrombolysis for STEMI. While thrombolysis may seem like a good choice, many patients have a contraindication and could end-up using more resources. Also, with a high probability of the angiogram showing non-obstructed coronary arteries during acute infections, primary PCI should be the preferred strategy. Copyright (c) 2020 Elsevier Inc. All rights reserved.

Powered by Koha